Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma

Drug Delivery

Volumn 18, Issue 2, 2011, Pages 143-149

  Kang, Sung Nam ^a   Lee, Eunmyong ^a   Lee, Mi Kyung ^b   Lim, Soo Jeong ^a  

^a Sejong University   (South Korea)

^b Woosuk University   (South Korea)

Author keywords

Cancer; Emulsion; Melanoma; Pro drug; Tributyrin

Indexed keywords

1, 2 DIMYRISTOYL SN GLYCERO 3 PHOSPHOCHOLINE; ANTINEOPLASTIC AGENT; BUTYRIC ACID; CASPASE 3; POLYSORBATE 80; PROCASPASE 3; SURFACTANT; TRIBUTYRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; EMULSION; ENZYME ACTIVATION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTYRATES; CELL GROWTH PROCESSES; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMULSIONS; HISTONE DEACETYLASE INHIBITORS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASTIC STEM CELLS; PARTICLE SIZE; POLYSORBATES; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

EID: 78650794154     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.522610     Document Type: Article

References (24)

1. Augenlicht, L.H., Mariadason, J.M., Wilson, A., Arango, D., Yang, W., Heerdt, B.G. Velcich, A. (2002). Short chain fatty acids and colon cancer. J Nutr. 132:3804S-8S.
2. Berwick, M., Wiggins, C. (2006). The current epidemiology of cutaneous malignant melanoma. Front Biosci. 11:1244-54.
3. Chen, Z.X., Breitman, T.R. (1994). Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res. 54:3494-9.
4. Chowdhury, R., Chowdhury, S., Roychoudhury, P., Mandal, C., Chaudhuri, K. (2009). Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis. 14:108-23.
5. Clarke, K.O., Feinman, R., Harrison, L.E. (2001). Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3. Cancer Lett. 171:57-65.
6. Conley, B.A., Egorin, M.J., Tait, N., Rosen, D.M., Sausville, E.A., Dover, G., Fram, R.J., Van Echo, D.A. (1998). Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res. 4:629-34.
7. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M.A., Lassota, P., Traganos, F. (1992). Features of apoptotic cells measured by flow cytometry. Cytometry. 13:795-808.
8. Driscoll, D.F. (2006). Lipid injectable emulsions: Pharmacopeial and safety issues. Pharm Res. 23:1959-69.
9. Giermasz, A., Nowis, D., Jalili, A., Basak, G., Marczak, M., Makowski, M., Czajka, A., Mlynarczuk, I., Hoser, G., Stok Osa, T., Lewandowski, S., Jakobisiak, M. (2001). Antitumor activity of tributyrin in murine melanoma model. Cancer Lett. 164:143-8.
10. Hakem, R., De La Pompa, J.L., Elia, A., Potter, J., Mak, T.W. (1997). Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet. 16:298-302.
11. Heerdt, B.G., Houston, M.A., Anthony, G.M., Augenlicht, L.H. (1999). Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity. Cancer Res. 59:1584-91.
12. Jilaveanu, L.B., Aziz, S.A., Kluger, H.M. (2009). Chemotherapy and biologic therapies for melanoma: Do they work? Clin Dermatol. 27:614-25.
13. Kuwajima, A., Iwashita, J., Murata, J., Abe, T. (2007). The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res. 27:4163-9.
14. Li, Y., Le Maux, S., Xiao, H., Mcclements, D.J. (2009). Emulsion-based delivery systems for tributyrin, a potential colon cancer preventative agent. J Agric Food Chem. 57:9243-9.
15. Liu, L.T., Chang, H.C., Chiang, L.C., Hung, W.C. (2003). Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63:3069-72.
16. Marks, P.A., Richon, V.M., Rifkind, R.A. (2000). Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 92:1210-6.
17. Munshi, A., Kurland, J.F., Nishikawa, T., Tanaka, T., Hobbs, M.L., Tucker, S.L., Ismail, S., Stevens, C., Meyn, R.E. (2005). Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 11: 4912-22.
18. Pulukuri, S.M., Gorantla, B., Rao, J.S. (2007). Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem. 282:35594-603.
19. Schroder, C., Eckert, K., Maurer, H.R. (1998). Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Int J Oncol. 13:1335-40.
20. Su, J., Ho, P.C. (2004). Preparation of tributyrin emulsion and characterization of the binding of the emulsion particles to low-density lipoprotein in vitro. J Pharm Sci. 93:1755-65.
21. Utley, R.T., Ikeda, K., Grant, P.A., Cote, J., Steger, D.J., Eberharter, A., John, S., Workman, J.L. (1998). Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature. 394:498-502.
22. Weisberg, E., Catley, L., Kujawa, J., Atadja, P., Remiszewski, S., Fuerst, P., Cavazza, C., Anderson, K., Griffin, J.D. (2004). Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia. 18:1951-63.
23. Zielinska, K., Wilk, K.A., Jezierski, A., Jesionowski, T. (2008). Microstructure and structural transition in microemulsions stabilized by aldonamide-type surfactants. J Colloid Interface Sci. 321:408-17.
24. Zimra, Y., Wasserman, L., Maron, L., Shaklai, M., Nudelman, A., Rephaeli, A. (1997). Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. J Cancer Res Clin Oncol. 123:152-60.